Total Clarity Wealth Management, Inc. Autolus Therapeutics PLC Transaction History

Total Clarity Wealth Management, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 29, 2022	BUY	$2.04 - $4.68 $2,448 - $5,616	1,200 New	1,200 $3,000
Q1 2022 Apr 29, 2022	SELL	$3.52 - $5.46 $4,224 - $6,552	-1,200 Closed	0 $0
Q4 2021 Feb 03, 2022	SELL	$5.1 - $7.0 $15,299 - $21,000	-3,000 Reduced 71.43%	1,200 $6,000
Q3 2021 Oct 21, 2021	BUY	$5.32 - $7.37 $22,344 - $30,954	4,200 New	4,200 $28,000
Q2 2021 Jul 26, 2021	SELL	$4.78 - $7.96 $4,780 - $7,960	-1,000 Closed	0 $0
Q1 2021 May 05, 2021	BUY	$5.49 - $9.36 $5,490 - $9,360	1,000 New	1,000 $6,000

104

163M

2.8K

13.4K

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $208M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

Get notified when there are updates to the investment portfolio of Total Clarity Wealth Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Total Clarity Wealth Management, Inc. with notifications on news.